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Background: Viral hepatitis is a major health problem worldwide. Change in transmission patterns of hepatitis B makes it necessary to re-evaluate its prevalence and risk factors.
Objectives: We aimed to determine the prevalence of HBV infection and its related risk factors in Amol city, Northern Iran.
Patients and Methods: As a population based study, a cluster sampling approach was used and 6146 individuals from the general population of urban and rural areas of Amol, Iran, from both genders and different ages were enrolled. Inclusion criteria were willingness to participate in the study, being a lifelong resident in Amol city or its surrounding areas with Iranian nationality. Ten milliliters (10 mL) of blood was taken from each study subject and checked regarding hepatitis B markers including HbsAg, HBsAb and HBcAb using a third generation ELISA. The prevalence of HBV infections and its potential risk factors were recorded.
Results: The prevalence of HBsAg, HBsAb and HBcAb were estimated as 0.9%, 30.7% and 10.5%, respectively. The mean age of all participants was 43.9 (95% CI: 43.4, 44.3) in females and 55.6 in (n = 3472) males. In our study, there was a significant association between family history of hepatitis, rural residency and presence of HBsAg. There was also a positive correlation between HBcAb and family history of hepatitis, history of other types of hepatic diseases, history of tattooing, traditional phlebotomy, male gender and age. In backward logistic regression, a significant association was found between history of hepatitis in first-degree family members (OR = 13.35; 95% CI: 6.26, 28.47) and place of residence (OR = 2.32; 95% CI: 1.27, 4.22) with presence of HBsAg. There was also a positive correlation between history of hepatitis among first-degree family members (OR = 2.49; 95% CI: 1.52, 4.08), history of tattooing (OR = 2.13; 95% CI: 1.33, 3.42), history of previous hepatitis (OR = 1.87; 95% CI: 1.06, 3.28), male sex (OR = 1.36; 95% CI: 1.12, 1.66) and age (OR = 1.03; 95% CI: 1.03, 1.04) with presence of HBcAb.
Conclusions: The prevalence of hepatitis B in Amol City and its surrounding areas was about one percent, a lower rate than other reports from Iran.
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1. BackgroundIt is estimated that more than 400 million individuals have hepatitis B (HBV) infection worldwide. This infec-tion is one of the top ten leading causes of death overall (1-3). In this context, understanding regional and demo-graphic specific prevalence of hepatitis B infection is an important issue for evaluation, national prevention pro-grams and control of disease. A matter of greater impor-tance is assessment of the prevalence of HBV infection regarding its transmission and demographic variation in each territory. However, global seroprevalence sta-tistics of HBV cannot explain each region current situa-tion, morever vaccination and other preventive policies around the world peobably make changing the epidemi-ological schema of HBV around the world.The prevalence of hepatitis B varies among different countries ranging from 0.1% in Western countries to 35% 
in Southeast of Asia (3-5). The prevalence of hepatitis B infection in the Middle East varies among its geographic areas. While Kuwait and Bahrain have a low prevalence of hepatitis B infection of about 2%, countries like Iraq and United Arab Emirates have a prevalence of 2-5% (6, 7).The prevalence of HBV infection in Iran varies within its geography (8). Recent data showed the overall preva-lence of HBV in Iran as less than 3% (8, 9). Despite the fact, the prevalence of hepatitis B surface antigen in Iran has declined significantly during the last two decades from 3.4-8% in 1979 to 1-3% in 2000 (8, 9). So far, chronic hepati-tis B remains the cause of more than 50% of cirrhosis and HCC in Iran (8, 10, 11). According to a systemic review in 2008, the seroprevalence of HBV in Iran was reported as 2.14%, although it did not reflect all provinces of Iran (12). In addition, a nationwide study performed by the Iranian 
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Blood Transfusion Organization demonstrated that the rate of HBV infection among volunteer blood donors had decreased from 1.8% to 0.4% between 1998 and 2007 (13). A rise in general public awareness about HBV transmission along with the mass vaccination program from 1993 for all neonates and healthcare workers and those at risk of HBV infection have influenced the outcome (11, 14). Despite these studies, there is not enough data information about the epidemiology of HBV infection in various parts of Iran.Furthermore, it seems that risk factors vary among dif-ferent regions within the country; thus, determination of risk factors and establishment of the main routes of HBV transmission could in turn help health administra-tions design effective prevention policies.Prevalent routes of HBV transmission include prenatal infection, sexual contact, intravenous narcotic use and transfusion. The most common route of transmission of hepatitis B in Iran was vertical transmission in the past, but other routes of transmission should also be consid-ered. Although global vaccination program against hepa-titis B decreased the rate of hepatitis B carriers, the rate of hepatitis B infected subjects remains noticeably high. This may reflect changes in patterns of epidemiology and transmission of HBV, producing some problems for healthcare systems (14-17).
2. ObjectivesIn this study, we tried to determine the prevalence and common risk factors of HBV infection in Amol city, Ma-zandaran province, Northern Iran.
3. Patients and Methods
3.1. Study Area and PopulationMazanderan province is located in North of Iran and Amol is a large city within this area with a population of more than 300000. There is an almost equal distribution regarding the number of its rural and urban inhabitants, providing adequate sample size for comparison between these inhabitants. Furthermore, due to a low rate of mi-gration to and from this area, the ethnicity of the resi-dents has to a large extent remained unchanged largely.The study was performed as a part of a health cohort conducted in Amol from 2008 to 2011, by the Gastrointes-tinal and Liver Disease Research Centre (GILDRC) on the above population to determine the prevalence of HBV infection and its risk factors. Those enrolled were older than 10 years. Urban areas were considered as urbanized municipal areas and rural areas were those with agricul-tural areas. Inclusion criteria were Iranian nationality, lifelong residency in Amol or its vicinity, and willingness to participate in the study.
3.2. Sample of StudyA clustered random sampling was used, and Health Centers (HC) were considered as clusters. Each health 
center provided services to an average of 30 households. In this study, 24 and 16 urban and rural health centers were selected, respectively. From each health center, households were selected randomly. Then from each family, one male and one female member were chosen randomly. Finally, the total population was 6146 sub-jects.
3.3. Data Collection and Laboratory TestsThe researchers held face-to-face interviews with par-ticipants in health centers, between 2008 and 2011. When participants failed to attend their three sched-uled interviews, an appointment was offered at their homes. When a subject refused to participate in this study, they were replaced other participants from their same cluster. Subjects were asked to complete a ques-tionnaire containing information about age (number of years according to their Identification documents), gender (male or female), marital status (single or mar-ried based on the subject's own responses), family his-tory (first degree relative: father, mother, wife/husband, siblings; second degree relatives: uncles, aunts; third de-gree relatives: extended family), occupation (high-risk jobs such as medical staff and nursing home workers), literacy level (five level: illiterate, < 6 years of schooling, ≤ 12 years of schooling, ≤ bachelor's degree holder, ≥ master's degree holder), blood transfusion history, his-tory of surgery (both minor and major operation), viral hepatitis (hepatitis C, hepatitis B), narcotic drug use (usual use of narcotics or drugs more than once weekly), smoking (active smoker or passive), tattooing and pierc-ing (presence of figures, or sign or scars), cupping and blood-letting (yes or no; based on the response of sub-jects to question). All those eligible to participate were referred to the Amol Research Station (ARS) in the Haraz Clinic, affiliated to the GILDRC, for completion of clini-cal and laboratory evaluations. HBV markers including HbsAg, HBsAb and HBcAb were evaluated using a third generation ELISA (Enzyme-Linked Immuno-Sorbent As-say) method by Acon kits (Acon lab. San Diego. CA92121, USA).
3.4. Statistical AnalysisData was analyzed using STATA software, version 12 (StataCorp, Texas, USA). Since data were considered as aggregated and our sampling was clustered, we used survey data analysis methods for all computations. Each health center was considered a cluster and each partici-pant was designated to a certain cluster. Health centers defined as ‘strata’ and the population represented by each strata used for ‘finite population correction’ using STATA ‘survey data analysis’. The data was weighted by the proportion of the population represented by each strata (health centers) to the selected subjects num-ber of each health centers. We used survey data analy-sis methods to estimate more accurate HBV infection 
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prevalence and risk factors including weighted point estimates prevalence rates of HBV biomarkers and their estimated 95% confidence intervals. ‘Proportions for survey data’ were used to calculate proportions and 95% confidence intervals. ‘Means estimate for survey data’ were used to calculate means and 95% confidence intervals. A ‘two-way table for survey data’ was used to investigate the association between HBV biomarkers and other variables. All confidence intervals, chi-square and P-values reported here were corrected for the clus-ter survey design using STATA ‘survey data analyses. ‘Logistic regression for survey data (backward method)’ was used to identify predictors of high-risk hepatitis B infection. All variables with p-values less than 0.20 were included in this model. A P value less than 0.05 was con-sidered significant.
3.5. EthicsParticipants were informed about the project and writ-ten consent was obtained from all of them before data collection. All data was securely recorded in the study database. The study protocol and consent form were ap-proved by the Board of Ethics of the GILDRC.
4. Results
4.1. Statistical Characteristics of SubjectsFrom 7000 subjects who were invited, 6146 cases (re-sponse rate = 87.8%) accepted to participate. Sixty-four subjects were excluded because of uncompleted data. Of 6146 subjects 3472 (55.6%) were male. The mean age of participants was 43.9 (95% CI: 43.4, 44.3) and 3006 (38.7%) were from rural areas. The mean age of rural participants was 43.54 (95% CI: 42.7, 44.06) and 63% (n = 1893) were male. For urban cases, these values were 44.2 (95% CI: 43.5, 44.8) and 50.9% (n = 1579), respectively. Of all participants, 
286 (4.6%) individuals were younger than 18 years.
4.2. Prevalence of HBV MarkersUsing survey data analysis method, the prevalence of HBsAg, HBsAb and HBcAb were estimated as 0.9% (95% CI: 0.6, 1.2%), 30.7% (95% CI: 29.3, 32%) and 10.5% (95% CI: 9.6, 11.4%), respectively. In total, 286 individuals were younger than 18 years, of whom 98 (37.8%) had HBsAb levels more than ten microliters. Moreover, 459 (8.27%) individuals had positive results for both HBsAb and HB-cAb (Resolved infection) and 1231 (22.43%) individuals were HBsAb positive but HBcAb negative (Table 1).
4.3. Prevalence of HBV Risk FactorsDistribution of potential HBV risk factors between pos-itive HBsAg and HBcAb subjects were shown in Table 2. Family history of hepatitis, rural residency and history of surgery were significantly associated with presence of HBsAg. Furthermore, there was a significant associa-tion between family history of hepatitis, family history of cirrhosis, male gender, history of traditional phle-botomy and history of tattooing with the presence of HBcAb.
4.4. Association Between HBV Markers and its 
Risk FactorsLogistic regression analysis was used to calculate the odds ratios for main risk factors (Tables 3 and 4). In univar-iate logistic regression (model 1), there was a significant association between history of hepatitis in family mem-bers (OR = 12.77), rural region residents (OR = 2.15), and the presence of HBsAg. There was also a positive correlation between HBcAb and history of hepatitis in family mem-bers (OR = 2.7), history of other types of hepatic diseases (OR = 1.9), history of tattooing (OR = 1.7), traditional phle-botomy (OR = 1.5), male sex (OR = 1.3) and age (OR = 1.03).
Table 1.  Prevalence of Hepatitis B Markers Among All Participants Regarding Gender and Location a
HBV Markers Total Urban Rural
Male Female Male Female
HBsAg+ b 62 (0.92) 16 (0.92) 6 (0.34) 27 (1.39) 13 (1.32)
HBsAb+ c 1693 (30.73) 438 (31.79) 456 (35.12) 513 (27.26) 286 (25.99)
HBcAb+ d 639 (10.56) 190 (12.38) 128 (8.57) 213 (11.15) 108 (9.79)
HBsAb+ and HBcAb+ 459 (8.27) 127 (9.7) 93 (6.99) 156 (8.24) 83 (7.98)
HBsAb+ and HBcAb- 1231 (22.43) 311 (22.11) 363 (28.12) 356 (18.99) 201 (17.85)
HBsAb- and HBcAb+ 144 (2.26) 39 (2.61) 24 (1.62) 57 (2.9) 24 (1.72)a  Data are presented as No. (%).b  Hepatitis B surface antigen.c  Hepatitis B surface antibody.d  Hepatitis B core antibody.
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Table 2.  Distribution of HBV Risk Factors Regarding HBV Markers a
Variables HBsAg b HBcAb c
Total Positive P Value d Total Positive P Value e
Gender 0.001Male 3469 (57.08) 43 (1.13) 0.09 3469 (57.10) 403 (11.84)Female 2608 (42.91) 19 (0.65) 2606 (42.89) 236 (8.96)Total 6077 62 (1.02) 6075 639 (10.51)
Region 0.87Rural 3006 (49.46) 40 (1.36) 0.01 3003 (49.43) 321 (10.64)Urban 3071 (50.53) 22 (0.63) 3072 (50.56) 318 (10.51)Total 6077 62 (1.02) 6075 639 (10.51)
History of surgery 0.44Yes 2687 (44.53) 20 (0.63) 0.04 2684 (44.65) 301 (10.79)No 3326 (55.31) 41 (1.14) 3327 (55.34) 324 (10.11)Total 6013 61 (1.01) 6011 625 (10.39)
History of unsterile puncture 0.71Yes 1290 (21.42) 10 (0.57) 0.13 1288 (21.40) 135 (10.14)No 4730 (78.57) 51 (1) 4730 (78.59) 493 (10.52)Total 6020 61 (1.01) 6018 574 (9.53)
History of blood transfusion 0.06Yes 350 (5.81) 6 (1.88) 0.12 350 (5.81) 51 (13.68)No 5672 (94.18) 55 (0.85) 5670 (94.18) 577 (10.24)Total 6022 61 (1.01) 6020 628 (10.43)
History of traditional phlebotomy 0.002Yes 460 (7.63) 6 (1.15) 0.55 460 (7.64) 70 (15.13)No 5561 (92.36) 55 (0.89) 5559 (92.35) 558 (10.05)Total 6021 61 (1.01) 6019 628 (10.43)
Family history of hepatitis < 0.001First degree 145 (2.40) 14 (8.49) < 0.001 145 (2.40) 37 (23.53)Second degree 75 (1.24) 1 (1.28) 74 (1.22) 14 (15.69)Third Degree 53 (0.87) 0 53 (0.88) 8 (19.83)No 5750 (95.46) 46 (0.72) 5749 (95.48) 569 (9.95)Total 6023 61 (1.01) 6021 628 (1.04)
History of Tattooing 0.01Yes 194 (3.22) 4 (1.65) 0.26 194 (3.22) 26 (16.92)No 5828 (96.77) 57 (0.89) 5826 (96.77) 602 (10.24)Total 6022 61 (1.01) 6020 628 (10.43)
History of imprisonment 0.76Yes 86 (1.42) 1 (1.09) 0.85 86 (1.42) 9 (9.47)No 5933 (98.57) 60 (0.91) 5931 (98.57) 619 (10.47)Total 6019 61 (1.01) 6017 628 (10.43)
High risk occupational 0.25Yes 58 (0.96) 0 0.50 58 (0.96) 8 (15.65)No 5958 (99.03) 61 (0.92) 5956 (99.03) 620 (10.4)Total 6016 61 (1.01) 6014 628 (10.44)
History of unsafe sexual contact 0.43Yes 26 (0.43) 0 0.66 26 (0.43) 2 (6.20)No 5992 (99.56) 61 (0.91) 5990 (99.56) 626 (10.47)Total 6018 61 (1.01) 6016 628 (10.43)
History of IDU f 0.10Yes 27 (0.44) 0 0.64 27 (0.44) 0No 5994 (99.55) 61 (0.91) 5992 (99.55) 627 (10.48)Total 6021 61 (1.01) 6019 627 (10.41)a  Data are presented as No. (%).b  Hepatitis B surface antigen.c  Hepatitis B core antibody.d  P-value for HBV risk factors regarding HBsAg.e  P-value for HBV risk factors regarding HBcAb.f  Intravenous drug user.
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Table 3.  Logistic Regression for Assessing Association Between HbsAg and Related Risk Factors
Variables OR (95% CI) Model 1 a OR (95% CI) Model 2 b OR (95% CI) Model 3 c OR (95% CI) Model 4 d
GenderMale 1.72 (0.90 - 3.27) 1.72 (0 .90 - 3.27) 1.33 (0 .52 - 3.35) -Female Reference Reference Reference -
Age, y 1.00 (0.99 - 1.02) 1.00 ( 0.99 - 1.02) - -
RegionRural 2.15 (1.18 - 3.92) 2.05 ( 1.10 - 3.83) 2.32 ( 1.23 - 4.37) 2.32 (1.27 - 4.22)Urban Reference Reference Reference Reference
Family history of hepatitisFirst degree 12.77 (6 - 27.19) 13.68 (6.36 - 29.44) 12.60 (5.88 - 27.03) 13.35 (6.26 - 28.47)Second degree 1.79 (0.24 - 13.09) 1.88 (0.25 - 13.73) 1.54 (0.23 - 9.98) 1.73 (0.23 - 12.56)Third degree 0.29 (0.04 - 1.91) 0.35 (0.05 - 2.26) 0.38 (0.05 - 2.47) 0.33 (0.05 - 2.11)No Reference Reference Reference Reference
History of blood transfusion 2.22 (0.78 - 6.34) 2.21(0.74 - 6.63) 2.35 (0.81 - 6.76) -
History of surgery 0.55 (0.30 - 0.99) 0.56 (0.31 - 1.03) 0.55 (0.28 - 1.09) -
History of imprisonment 1.20 (0.16 - 8.73) 0.92 (0.12 - 6.78) - -
History of IDU e 1.74 ( 0.10 - 28.37) - - -
History of tattooing 1.87 (0.60 - 5.78) 1.89 (0.61 - 5.83) 1.87 (0.65 - 5.37) -
History of traditional phlebotomy 1.29 (0.54 - 3.12) 1.18 (0.46 - 2.99) - -
History of unsterile puncture 0.56 (0.27 - 1.18) 0.78 (0.29 - 2.08) 0.70 (0.25 - 1.90) -
High risk occupation 0.89 (0.05 – 14.32) - - -
History of Alcohol addiction 1.36 ( 0.41 - 4.53) 1.12 (0.33 - 3.83) - -
History of other types of hepatitis 1.99 (0.76 - 5.18) 1.97 (0.74 - 5.23) 1.63 (0.39 - 6.78) -
History of unsafe sexual contact 1.80 (0.11 - 29.46) - - -a  Crude Odds Ratio.b  Adjusted Odds Ratio for sex and age.c  Adjusted Odds Ratio (all variables with p-value < 0.2 entered the model such as sex, region, family history of hepatitis and history of blood transfusion, surgery, tattooing, unsterile puncture, icterus and other types of hepatitis).d  Multivariable backward logistic regression model.e  Intravenous drug user.
Table 4.  Logistic Regression for Assessing Association Between HBcAb and Related Risk Factors
Variables Model 1, OR (95% CI) a Model 2, OR (95% CI) b Model 3, OR (95% CI) c Model 4, OR (95% CI) d
GenderMale 1.36 (1.12 - 1.64) 1.03 (1.03 - 1.04) 1.37 (1.12 - 1.67) 1.36 (1.12 - 1.66)Female Reference Reference Reference Reference
Age, y 1.03 ( 1.03 - 1.04) 1.34 (1.11 - 1.63) 1.03 (1.03 - 1.04) 1.03 (1.03 - 1.04)
Region Rural 1.01 (0.84 - 1.21) 0.99 (0.82 - 1.20) - -Urban Reference Reference - -
Family history of hepatitisFirst degree 2.78 (1.81 - 4.26) 2.13 (1.98 - 4.97) 2.40 (1.45 - 3.97) 2.49 (1.52 - 4.08)Second degree 1.68 (0.88 - 3.21) 1.77 (0.91 - 3.42) 1.31 (0.69 - 2.46) 1.39 (0.74 - 2.61)Third degree 2.23 (0.94 - 5.29) 2.76 (1.06 - 7.13) 2.50 (0.97 - 6.43) 2.50 (0.97 - 6.43)No Reference Reference Reference Reference
History of blood transfusion 1.38 (0.97 - 1.97) 1.17 (0.81 - 1.70) - -
History of surgery 1.07 (0.89 - 1.29) 0.92 (0.76 - 1.12) - -
History of imprisonment 0.89 (0.43 - 1.82) 0.64 (0.31 - 1.34) - -
History of IDU e 1.42 (0.009 - 2.51) - - -
History of tattooing 1.78 (1.11 - 2.84) 2.19 (1.36 - 3.52) 2.14 (1.33 - 3.43) 2.13 (1.33 - 3.42)
History of traditional Phlebotomy 1.59 (1.17 - 2.15) 1.10 (0.81 - 1.50) 1.06 (0.77 - 1.45) -
History of unsterile puncture 0.95 (0.76 - 1.19) 1.05 (0.79 - 1.40) - -
High risk occupation 1.59 (0.70 - 3.59) 1.79 (0.79 - 4.07) - -
History of Alcohol addiction 1.12 (0.67 - 1.88) 1.21 (0.71 - 2.05) - -
History of other types of hepatitis 1.99 (1.07 - 3.72) 1.95 (1.14 –3.33) 1.84 (1.04 - 3.25) 1.87 (1.06 - 3.28)
History of unsafe sexual contact 0.56 (0.13 - 2.40) 0.65 (0.15 - 2.88) - -a  Crude Odds Ratio.b  Adjusted Odds Ratio for sex and age.c  Adjusted Odds Ratio (all variables with p-value < 0.2 entered the model such as sex, age, family history of hepatitis, family history of cirrhosis and history of tattooing, traditional phlebotomy, icterus and other types of hepatitis).d  Multivariable backward logistic regression model.e  Intravenous drug user.
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In multivariable logistic regression, after adjustment for demographic variables such as age and sex (Model 2), there was a significant association between family history of hepatitis (OR = 13.6), and rural residency (OR = 2) with the presence of HBsAg. There was also a positive correlation between HBcAb and history of tattooing (OR = 2.1), family history of hepatitis B (OR = 2.1) and history of other types of hepatic diseases (OR = 1.95) in a similar model adjusted for age and sex.In model 3, all variables with p-values less than 0.2 in-cluded in the model. There was a significant association between history of hepatitis in family members (OR = 12.6) and rural region (OR = 2.3) with the presence of HB-sAg. Finally, in the backward method of multivariable logistic regression (model 4), we found a significant asso-ciation between history of hepatitis in first relative mem-bers (OR = 13.3) and region (OR = 2.3) with the presence of HBsAg. A history of hepatitis in first-degree relatives (OR = 2.4), history of tattooing (OR = 2.1), history of other types of hepatitis disease (OR = 1.8), male sex (OR = 1.3) and age (OR = 1.03) with the presence of HBcAb in this model (Tables 3 and 4).
5. DiscussionIn this survey, serum samples of 6082 subjects were evaluated for the presence of HBsAg and HBcAb. Accord-ing to our survey analyses, the prevalence of HBsAg and HBcAb were 0.9% and 10.5%, respectively.In our study, the prevalence of HbsAg as an indicator of chronic hepatitis B infection was lower than other parts of Iran and lower than the national prevalence rate. Zali et al. and Alavian et al. revealed a prevalence of 1.7% and 2.14% for HBsAg in the general population of Iran (8, 12), indicating that the rate of HBV infection does not follow a consistent pattern in various geographical areas with-in the country. Table 5 summarizes some population based studies published on the prevalence of HBsAg in Iran. According to these studies, the highest prevalence of HBV infection was in Golestan province (18) northeast of Iran and the lowest rate of HBV infection in Azarbay-jan province (12) northwest of Iran. Although, the fre-quency of hepatitis B was significantly different in Amol located between these two areas and adjacent to Goles-tan province (0.9% vs. 5.1%). We could not express a clear explanation about these differences, but it might be due to lifestyle, population density, interfamilial contact, public education about HBV infection and successful anti HBV vaccination. Nationwide vaccination against HBV was introduced in Iran since 1992; therefore, sub-jects younger than 18 years had received vaccination against HBV. In this population, lower expected number of subjects with positive HBsAb (37.8%) might be due to the decreasing level of antiHBs during the time after vaccination.HBcAb is another marker of viral hepatitis B and an indicator of past exposure to HBV. Positive results for 
HBcAb could be considered as a potential threat for transmission of hepatitis B infection (19, 20). More-over, a noticeable proportion of population with posi-tive HBcAb has occult HBV infection with undetectable HBV- DNA and negative results for serum HBsAg. In this situation, further follow-up and careful evaluation of patients is needed. However, the prevalence of this HBV marker is not similar in different geographic areas of Iran. As illustrated in Table 5, our results showed a lower prevalence of HBcAb compared to other parts of Iran (12, 18, 19, 21-24). It seems that cultural factors and lack of accurate implementation of health guidelines might affect the distribution of HBV infection. The differences between prevalence of hepatitis B markers in differ-ent parts of Iran may be related to some traditional lifestyle factors, population density, public knowledge and education about HBV transmission. Mass vaccina-tion program and active follow-up of patients with HBV infection by health service providers had a significant influence on the rate of infection. However, it is not an easy task to compare different prevalence rates among provinces of Iran.
Table 5.  The Prevalence of HbsAg and HBcAb in Various Prov-inces of Iran
Province HBcAb HbsAg Author
Sistan Balochestan 23.58 3.38 Salehi et al. (2012) (21)
Golestan 36.9 5.1 Merat et al. (2009) (18)
Hormozgan 13.3 2.7 Merat et al. (2009) (18)
Tehran 14.2 2.3 Merat et al. (2009) (18)
Khorasan-e-Razavi - 1.39 Fathimoghaddam et al. (2011) (23)
Qom - 1.3 Ghadir et al. (2012) (24)
Azarbayjan - 1.2 Alavian et al. (2008) (12)
Mazandaran 10.5 1 Present study
Fars 6.55 - Behbahani et al. (2006) (22)
Multivariate analysis showed that HBsAg positivity was significantly correlated with family history of hepa-titis and rural residency as independent risk factors. Our results revealed that all age groups and particularly males had exposure to HBV. Furthermore, family history, tattooing, male gender, age of hepatitis and tattooing had significant correlations with the presence of HBcAb (Tables 3 and 4).In almost all previous studies in Iran, age was con-sidered a predictive risk factor in accordance with our study (Figure 1) (17, 18, 23, 25). This fact could be attrib-uted to the mass national vaccination program in Iran from 1992 covering the young population; therefore, older populations had not received vaccination against HBV and are more prone to HBV infection through vari-

















Figure 1. The Prevalence of HBV Markers Related to Age Groups
In concordance with other published reports, our find-ings showed that HBV infection is more common in males than females (12, 18, 23). Although in the forward regression analysis of our study, there was an association between HBsAg and gender, while the backward regres-sion analysis did not show the same result. Alavian et al. revealed a higher prevalence of HBV among men than women in Iran (2.55% vs. 2.03% respectively) (12). Some re-search groups did not find a difference between genders (9, 18, 23, 25). This difference could be related to higher exposure of males to hepatitis B risk factors.In a study on 1264 HBV positive subjects, it was con-cluded that family history of hepatitis, history of dental surgery, history of transfusion and marriage were risk factors of infection. Therefore, marriage status can be considered as an interfamilial transmission in adults who have not received vaccination (23, 26).There are a limited number of studies comparing the prevalence of HBV infection in rural and urban areas in Iran. In our study, the prevalence of HBsAg in rural areas was twice as high as urban areas (1.36% vs. 0.63%). This re-sult is comparable with the findings of other investiga-tors in different provinces of Iran (25). However, the rates of HBcAb in urban and rural areas in the current study were quite similar (10.51% and 10.64%, respectively).In conclusion, the prevalence of HBV infection in the north central province, northern Iran was almost lower than other reports from Iran country. Moreover, continu-ing public education about hepatitis B as well as adequate vaccination and screening programs among high-risk groups should be considered to control the infection.
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